- Report
- September 2026
- 354 Pages
Global
From €6384EUR$6,995USD£5,471GBP
- Report
- May 2026
- 469 Pages
Global
From €4518EUR$4,950USD£3,871GBP
- Report
- October 2025
- 691 Pages
Global
From €4518EUR$4,950USD£3,871GBP
- Report
- February 2026
- 200 Pages
Global
From €2729EUR$2,990USD£2,339GBP
- Report
- November 2025
- 405 Pages
Global
From €4107EUR$4,500USD£3,519GBP
- Report
- January 2026
Global
From €4472EUR$4,900USD£3,832GBP
- Report
- September 2026
- 196 Pages
Global
From €3236EUR$3,545USD£2,773GBP
€3595EUR$3,939USD£3,081GBP
- Report
- September 2026
- 181 Pages
Global
From €3236EUR$3,545USD£2,773GBP
€3595EUR$3,939USD£3,081GBP
- Report
- September 2026
- 185 Pages
Global
From €3236EUR$3,545USD£2,773GBP
€3595EUR$3,939USD£3,081GBP
- Report
- September 2026
- 194 Pages
Global
From €3236EUR$3,545USD£2,773GBP
€3595EUR$3,939USD£3,081GBP
- Report
- September 2026
- 190 Pages
Global
From €3236EUR$3,545USD£2,773GBP
€3595EUR$3,939USD£3,081GBP
- Report
- September 2026
- 183 Pages
Global
From €3236EUR$3,545USD£2,773GBP
€3595EUR$3,939USD£3,081GBP
- Report
- May 2026
- 135 Pages
Global
From €2737EUR$2,999USD£2,346GBP
€3650EUR$3,999USD£3,128GBP
- Report
- April 2026
- 148 Pages
Global
From €2737EUR$2,999USD£2,346GBP
€3650EUR$3,999USD£3,128GBP
- Report
- April 2026
- 150 Pages
Global
From €2737EUR$2,999USD£2,346GBP
€3650EUR$3,999USD£3,128GBP
- Report
- October 2025
- 181 Pages
Global
From €4107EUR$4,500USD£3,519GBP
- Report
- September 2026
- 275 Pages
Global
From €5339EUR$5,850USD£4,575GBP
- Report
- September 2026
- 149 Pages
Global
From €5339EUR$5,850USD£4,575GBP
- Report
- September 2026
- 576 Pages
Global
From €5339EUR$5,850USD£4,575GBP
- Report
- September 2026
- 474 Pages
Global
From €5339EUR$5,850USD£4,575GBP

The Hospital Acquired Infection (HAI) market is a subset of the Infectious Diseases Drugs market. HAIs are infections that occur in a hospital setting, and can be caused by a variety of bacteria, viruses, and fungi. These infections can be difficult to treat, as they are often resistant to antibiotics. As such, HAI drugs are designed to target specific pathogens, and are often used in combination with other treatments.
The HAI market is driven by the increasing prevalence of antibiotic-resistant infections, as well as the need for more effective treatments. Additionally, the rising number of hospitalizations due to chronic illnesses has also contributed to the growth of the market.
Some of the major players in the HAI market include Merck & Co., Pfizer, GlaxoSmithKline, Sanofi, and Johnson & Johnson. These companies are actively developing new drugs and treatments to address the growing prevalence of HAIs. Show Less Read more